Bemiparin sodium; Enoxaparin sodium
A Multinational, Multicentre, Randomized, Open, Parallel Group Study on the Efficacy and Safety of Bemiparin Sodium (LMWH) Compared to Enoxaparin Sodium (LMWH) in the Treatment of Acute Deep Vein Thrombosis (DVT)
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT01880216/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–100 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 312 чел. во всех странах исследования.
- Центров в реестре: 20 в 12 городах. Список — ниже на странице.
- Плановая дата окончания (05.2015) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 3 · невключение: 17
Критерии включения
- Patients with acute deep-vein thrombosis of the leg (DVT) with symptoms of less than 14 days confirmed by complete compression ultrasound (cCUS) within 48 h prior study starting .
- Males and females aged ≥18 years
- Patients who have given their written informed consent.
Критерии невключения
- Specific
- History and presence of familial bleeding diathesis, presence of active bleeding contraindicating anticoagulant therapy, as well as presence of clinically relevant coagulation - and clotting factor disorder,and thrombocytopenia
- Patients having undergone thrombectomy, having had insertion of a caval filter or who were treated with a fibrinolytic agent to treat the current episode of DVT
- Treatment with heparin (fractionated or unfractionated), fondaparinux or vitamin K antagonist or warfarin for treatment of DVT for more than 48 h prior to enrolment
- Long-term treatment with vitamin K antagonists, i.e. for atrial fibrillation, myocardial infarction or cardiomyopathy
- Isolated distal calf vein thrombosis
- Isolated superficial vein thrombosis
- Any other symptomatic venous thromboembolism beside of DVT
- Known hypersensitivity to heparin (including other pig-derived substances), to the study medications and heparin-derivatives including other LMWHs, warfarin and/or to the active ingredient or any excipient of the study medications
- Concurrent treatment with platelet function inhibitors (such as acetylsalicylic acid, ticlopidine, clopidogrel, NSAID), fibrinolytic agents and other anticoagulant agents, Glycoprotein IIb/IIIa receptor- antagonists, nitro-glycerine iv, systemic glucocorticoids, penicillin in high doses, dextran, ascorbic acid, digitalis, tetracycline, medical products that could increase the potassium plasma level
- History of documented or suspected heparin-induced thrombocytopenia (HIT I and II) or platelet count less than 100,000 platelets per mm3
- Ischaemic stroke one month prior to enrolment
- History of or active intracranial disorder (cerebral vascular aneurysm, arterio-venous malformation or cerebral neoplasm), history of haemorrhagic stroke or other intracranial bleeding 6 months prior to enrolment, active haemorrhage or increased risk of bleeding due to impaired haemostatics or organ lesion (e.g. peptic ulcer, hepatic failure, haemorrhagic stroke, macroscopic visible urogenital bleeding, cerebral vascular aneurysm or cerebral neoplasm) 1 month prior to enrolment.
- Uncontrolled arterial hypertension: systolic blood pressure > 200 mmHg and diastolic blood pressure > 105 mmHg.
- Severe impairment of pancreas function, history of gastro-duodenal ulcer disease, nephrolithiasis and/or ureterolithiasis, choroid and retinal vascular disease, suspected vascular retinopathy, vitreous haemorrhage or other intraocular bleedings, or any organic lesion with an increased risk of bleeding.
- Significant liver disease (e.g. acute hepatitis, chronic active hepatitis, hepatic cirrhosis, hepatic encephalopathy) or liver enzymes (ALT and/or AST) > 5x ULN.
- and others
Источник: ClinicalTrials.gov, NCT01880216 · запись обновлена в реестре 4 февраля 2016.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 1
- Percentage of patients with an improvement in thrombotic burden at Visit 3 — 83±7 days
Цель исследования
Deep-vein thrombosis (DVT) is a common but under-diagnosed medical condition that occurs when a thrombus forms in one of the large veins, usually in the lower limbs, leading to either partial or complete blocked circulation. The condition may progress to severe health complications, such as pulmonary embolism (PE), if not diagnosed and treated in a timely and effective manner.
The goal of the therapy for lower-extremity DVT is to prevent the extension of thrombus and pulmonary embolism in the short term and to prevent recurrent events in the long-term. Although anticoagulant therapy decreases the risk of recurrent thrombosis, the treatment also increases the risk for major hemorrhage.
This trial aims to optimize the current medical knowledge on the effectiveness and safety of two low molecular weight heparins, bemiparin and enoxaparin in the treatment of deep vein thrombosis.
Где проходит
20 центров в 12 городах- Federal Government Healthcare Institution «Hospital of the Russian Federation Internal Affairs Ministry in Moscow»
- Federally Funded State Institution «Institute of Surgery n.a. A.V. Vishnevskiy of the Ministry of Healthcare of Russian Federation»
- ГБУЗ города Москвы Городская клиническая больница № 1 им. Н.И. Пирогова ДЗМ (ГКБ № 1 им. Н.И. Пирогова)
- Federal State Budgetary Institution «Russian Center of Emergency and Radiation Medicine n.a. A.M. Nikiforov» of the Ministry of Russian Federation for Civil Defence, Emergencies and Elimination of Consequences of Natural Disasters
- Road Clinical Hospital of JSC «Russian Railways»
- Saint-Petersburg I.I. Dzhanelidze Research Institute of Emergency Medicine
- St.Petersburg Multi-Field City Hospital #2
- State Educational Institution «St Petersburg Medical Academy of Postgraduate Education» of Federal Agency of Public Health and Social Development
- СПб ГБУЗ «Городская больница № 26»
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT01880216 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.